Remove Bioavailability Remove Clinical Development Remove Trials
article thumbnail

Erasca receives fast track designation for glioblastoma therapy

Pharmaceutical Technology

The orally bioavailable small molecule EGFR inhibitor ERAS-801 demonstrated significant central nervous system (CNS) penetration in animal trials. This newly granted status helps Erasca to facilitate the development and review of ERAS-801, thereby accelerating the therapy’s reach to patients.

article thumbnail

Orphagen’s ACC therapy receives FDA rare pediatric disease status

Pharmaceutical Technology

OR-449 is a first-in-class, orally bioavailable, potent and selective small molecule antagonist of the orphan nuclear receptor steroidogenic factor-1 (SF-1, NR5A1). SF-1 is an important transcription factor for adrenal gland growth and development.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Zerion and Insud to develop Dispersome formulations of drugs

Pharmaceutical Technology

Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs. The finished product dosage form, clinical development and the final products’ marketing and sales across the globe will be handled by Insud. . All the clinical and other development expenses will be handled by Insud.

article thumbnail

Advances in Oncology Clinical Trials and Hematology: The Impact of BTK Inhibitors

XTalks

Mobasher Xtalks Clinical Edge is a magazine for clinical research professionals and all who want to be informed about the latest trends and happenings in clinical trials. It was engineered to have high potency, bioavailability and kinase selectivity that led to improved efficacy and safety in B-cell malignancies.

article thumbnail

Drug developers look at innovative mechanisms to tackle dry eye syndrome

Pharmaceutical Technology

cyclosporine A) is currently at pre-registration stage with the FDA, following results from late-stage clinical trials that demonstrated CyclASol significantly reduced corneal and conjunctival staining, and improved ocular dryness compared with vehicle. Novaliq’s CyclASol (0.1%

article thumbnail

Novartis’s Spartalizumab Combo Stubles; Union Therapeutics Doses In COVID-19 Trial; Yumanity To Merge With Proteostasis

Delveinsight

Novartis’s Spartalizumab Combo Fails To Meet The Primary Goal In The Melanoma Trial. The results announced that the spartalizumab combo stumbled in the trial and failed to hit the primary endpoint of investigator-assessed progression-free survival in melanoma.

Trials 52
article thumbnail

World Mental Health Day 2024: A Look at Recent Research

XTalks

If successful, this trial could pave the way for a New Drug Application (NDA) submission. With positive outcomes in preclinical models, EB-003 has confirmed oral bioavailability, adding to its therapeutic potential. This development highlights a growing interest in neuroplastogens as alternative mental health treatments.